Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 0 | 0 | 1,000 | 7,600 |
| Cost of Goods | N/A | N/A | N/A | 100 | 200 |
| Gross Profit | N/A | N/A | N/A | 900 | 7,400 |
| Operating Expenses | 28,274 | 31,513 | 37,869 | 42,950 | 32,894 |
| Operating Income | -28,274 | -31,513 | -37,869 | -41,950 | -25,294 |
| Other Income | 1,411 | 632 | 529 | 649 | 4,358 |
| Pre-tax Income | -26,863 | -30,881 | -37,340 | -41,301 | -20,936 |
| Income Tax | N/A | N/A | N/A | N/A | -237 |
| Net Income Continuous | -26,863 | -30,881 | -37,340 | -41,301 | -20,699 |
| Net Income | $-26,863 | $-30,881 | $-37,340 | $-41,301 | $-20,699 |
| EPS Basic Total Ops | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EPS Basic Continuous Ops | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EPS Diluted Total Ops | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EPS Diluted Continuous Ops | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EPS Diluted Before Non-Recurring Items | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EBITDA(a) | $-28,274 | $-31,513 | $-37,869 | $-41,950 | $-25,294 |